Cargando…

Clinical value of serum cholinesterase levels in Nephrotic syndrome: an observational study

BACKGROUND: Nephrotic syndrome (NS) results in massive proteinuria and hypoalbuminemia, which are responsible for a compensatory increase in protein synthesis in the liver. Serum cholinesterase (ChE) also increases in NS. However, its clinical value is not fully elucidated. METHODS: In this study, 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Goto, Kimihiko, Kono, Keiji, Fujii, Hideki, Goto, Shunsuke, Nishi, Shinichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976987/
https://www.ncbi.nlm.nih.gov/pubmed/35366840
http://dx.doi.org/10.1186/s12882-022-02764-0
_version_ 1784680680155774976
author Goto, Kimihiko
Kono, Keiji
Fujii, Hideki
Goto, Shunsuke
Nishi, Shinichi
author_facet Goto, Kimihiko
Kono, Keiji
Fujii, Hideki
Goto, Shunsuke
Nishi, Shinichi
author_sort Goto, Kimihiko
collection PubMed
description BACKGROUND: Nephrotic syndrome (NS) results in massive proteinuria and hypoalbuminemia, which are responsible for a compensatory increase in protein synthesis in the liver. Serum cholinesterase (ChE) also increases in NS. However, its clinical value is not fully elucidated. METHODS: In this study, 184 patients with NS who underwent kidney biopsy were included. The patients were divided into two groups according to serum ChE levels, as follows: hypercholinesterasemia (HC) and non-hypercholinesterasemia (NHC) groups. The clinical factors were compared between the two groups. RESULTS: The HC group had significantly more severe proteinuria and higher prevalence of high selective proteinuria than the NHC group. Furthermore, the prevalence of minimal change nephrotic syndrome (MCNS) was significantly higher in the HC group than that in the NHC group. Multivariate analysis revealed that the severity of proteinuria and MCNS were significantly associated with HC. CONCLUSION: In this study, HC in NS was associated with the severity of proteinuria and MCNS, and could help clinicians predict the histological diagnosis of NS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12882-022-02764-0.
format Online
Article
Text
id pubmed-8976987
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-89769872022-04-04 Clinical value of serum cholinesterase levels in Nephrotic syndrome: an observational study Goto, Kimihiko Kono, Keiji Fujii, Hideki Goto, Shunsuke Nishi, Shinichi BMC Nephrol Research BACKGROUND: Nephrotic syndrome (NS) results in massive proteinuria and hypoalbuminemia, which are responsible for a compensatory increase in protein synthesis in the liver. Serum cholinesterase (ChE) also increases in NS. However, its clinical value is not fully elucidated. METHODS: In this study, 184 patients with NS who underwent kidney biopsy were included. The patients were divided into two groups according to serum ChE levels, as follows: hypercholinesterasemia (HC) and non-hypercholinesterasemia (NHC) groups. The clinical factors were compared between the two groups. RESULTS: The HC group had significantly more severe proteinuria and higher prevalence of high selective proteinuria than the NHC group. Furthermore, the prevalence of minimal change nephrotic syndrome (MCNS) was significantly higher in the HC group than that in the NHC group. Multivariate analysis revealed that the severity of proteinuria and MCNS were significantly associated with HC. CONCLUSION: In this study, HC in NS was associated with the severity of proteinuria and MCNS, and could help clinicians predict the histological diagnosis of NS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12882-022-02764-0. BioMed Central 2022-04-02 /pmc/articles/PMC8976987/ /pubmed/35366840 http://dx.doi.org/10.1186/s12882-022-02764-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Goto, Kimihiko
Kono, Keiji
Fujii, Hideki
Goto, Shunsuke
Nishi, Shinichi
Clinical value of serum cholinesterase levels in Nephrotic syndrome: an observational study
title Clinical value of serum cholinesterase levels in Nephrotic syndrome: an observational study
title_full Clinical value of serum cholinesterase levels in Nephrotic syndrome: an observational study
title_fullStr Clinical value of serum cholinesterase levels in Nephrotic syndrome: an observational study
title_full_unstemmed Clinical value of serum cholinesterase levels in Nephrotic syndrome: an observational study
title_short Clinical value of serum cholinesterase levels in Nephrotic syndrome: an observational study
title_sort clinical value of serum cholinesterase levels in nephrotic syndrome: an observational study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976987/
https://www.ncbi.nlm.nih.gov/pubmed/35366840
http://dx.doi.org/10.1186/s12882-022-02764-0
work_keys_str_mv AT gotokimihiko clinicalvalueofserumcholinesteraselevelsinnephroticsyndromeanobservationalstudy
AT konokeiji clinicalvalueofserumcholinesteraselevelsinnephroticsyndromeanobservationalstudy
AT fujiihideki clinicalvalueofserumcholinesteraselevelsinnephroticsyndromeanobservationalstudy
AT gotoshunsuke clinicalvalueofserumcholinesteraselevelsinnephroticsyndromeanobservationalstudy
AT nishishinichi clinicalvalueofserumcholinesteraselevelsinnephroticsyndromeanobservationalstudy